^ abcMoret C, Grimaldi B, Massot O, Fillion G (April 2003). "The role and therapeutic potential of 5-HT-moduline in psychiatry". Seminars in Clinical Neuropsychiatry. 8 (2) ascnp50013: 137–146. doi:10.1053/scnp.2003.50013. PMID12728412.
^ abcdefFillion G (September 2000). "Potential of 5-HT-moduline as a drug target for affective disorders". Current Opinion in Investigational Drugs. 1 (1): 104–109. PMID11249585.
^ abFillion G, Rousselle JC, Massot O, Zifa E, Fillion MP, Prudhomme N (1996). "A new peptide, 5-HT-moduline, isolated and purified from mammalian brain specifically interacts with 5-HT1B/1D receptors". Behavioural Brain Research. 73 (1–2): 313–317. doi:10.1016/0166-4328(96)00120-9. PMID8788526.
^Massot O, Rousselle JC, Fillion MP, Grimaldi B, Cloëz-Tayarani I, Fugelli A, et al. (October 1996). "5-hydroxytryptamine-moduline, a new endogenous cerebral peptide, controls the serotonergic activity via its specific interaction with 5-hydroxytryptamine1B/1D receptors". Molecular Pharmacology. 50 (4): 752–762. doi:10.1016/S0026-895X(25)09375-7. PMID8863819.
^Seguin L, Seznec JC, Fillion G (March 1997). "The endogenous cerebral tetrapeptide 5-HT-moduline reduces in vivo the functional activity of central 5-HT1B receptors in the rat". Neuroscience Research. 27 (3): 277–280. doi:10.1016/s0168-0102(96)01150-9. PMID9129186.
^Rousselle JC, Plantefol M, Fillion MP, Massot O, Pauwels PJ, Fillion G (September 1998). "Specific interaction of 5-HT-moduline with human 5-HT1b as well as 5-HT1d receptors expressed in transfected cultured cells". Naunyn-schmiedeberg's Archives of Pharmacology. 358 (3): 279–286. doi:10.1007/pl00005254. PMID9774213.
^Grimaldi B, Fillion MP, Bonnin A, Rousselle JC, Massot O, Fillion G (August 1997). "Immunocytochemical localization of neurons expressing 5-HT-moduline in the mouse brain". Neuropharmacology. 36 (8): 1079–1087. doi:10.1016/s0028-3908(97)00099-3. PMID9294973.
^Massot O, Rousselle JC, Grimaldi B, Cloëz-Tayarani I, Fillion MP, Plantefol M, et al. (December 1998). "Molecular, cellular and physiological characteristics of 5-HT-moduline, a novel endogenous modulator of 5-HT1B receptor subtype". Annals of the New York Academy of Sciences. 861: 174–182. doi:10.1111/j.1749-6632.1998.tb10189.x. PMID9928255.
^Bentué-Ferrer D, Reymann JM, Rousselle JC, Massot O, Bourin M, Allain H, et al. (October 1998). "5-HT-moduline, a 5-HT(1B/1D) receptor endogenous modulator, interacts with dopamine release measured in vivo by microdialysis". European Journal of Pharmacology. 358 (2): 129–137. doi:10.1016/s0014-2999(98)00586-x. PMID9808261.
^Bourin M, Hascoët M (February 2001). "Drug mechanisms in anxiety". Current Opinion in Investigational Drugs. 2 (2): 259–265. PMID11816841.
^Grimaldi B, Bonnin A, Fillion MP, Prudhomme N, Fillion G (1999). "5-Hydroxytryptamine-moduline: a novel endogenous peptide involved in the control of anxiety". Neuroscience. 93 (4): 1223–1225. doi:10.1016/s0306-4522(99)00322-x. PMID10501445.
^Clénet F, Hascoët M, Fillion G, Galons H, Bourin M (December 2004). "Anxiolytic profile of HG1, a 5-HT-moduline antagonist, in three mouse models of anxiety". European Neuropsychopharmacology. 14 (6): 449–456. doi:10.1016/j.euroneuro.2003.12.004. PMID15589384.
^Clénet F, Hascoët M, Fillion G, Galons H, Bourin M (March 2005). "Role of GABA-ergic and serotonergic systems in the anxiolytic-like mechanism of action of a 5-HT-moduline antagonist in the mouse elevated plus maze". Behavioural Brain Research. 158 (2): 339–348. doi:10.1016/j.bbr.2004.09.015. PMID15698901.
^Plantefol M, Rousselle JC, Massot O, Bernardi E, Schoofs AR, Pourrias B, et al. (December 1999). "Structural requirements of 5-hydroxytryptamine-moduline analogues to interact with the 5-hydroxytryptamine1B receptor". Journal of Neurochemistry. 73 (6): 2617–2620. doi:10.1046/j.1471-4159.1999.0732617.x. PMID10582626.